Chemical inhibitors of C20orf77 function through various biochemical mechanisms to inhibit the protein's activity. Staurosporine, a well-known protein kinase inhibitor, disrupts the phosphorylation events that are critical for the activity of many proteins, including C20orf77. By inhibiting these kinases, Staurosporine can prevent the phosphorylation that C20orf77 might require for its function. Similarly, Wortmannin and LY294002, both phosphoinositide 3-kinases (PI3K) inhibitors, disrupt signaling pathways that C20orf77 relies upon. By inhibiting PI3K, these chemicals can prevent the activation of downstream targets that may be essential for the function of C20orf77. Rapamycin, by inhibiting the mammalian target of rapamycin (mTOR), can also disrupt downstream signaling pathways associated with C20orf77, potentially inhibiting its function. This is similar to the action of U0126 and PD98059, which selectively inhibit MEK1/2 and MEK respectively, thereby preventing the activation of the ERK pathway, a pathway that C20orf77 may depend on for its activity.
Furthermore, SB203580 targets p38 MAP Kinase, which is involved in response to stress and cytokines. Inhibition of p38 MAPK by SB203580 can interrupt signaling cascades that C20orf77 is part of, leading to its inhibition. SP600125, a JNK inhibitor, can halt signaling processes that are essential for C20orf77's activity. Triciribine aims at AKT inhibition, which prevents the phosphorylation and activation of proteins that are in the same pathway as C20orf77, thus leading to its functional inhibition. Dasatinib, a broad-spectrum tyrosine kinase inhibitor, can suppress the activity of kinases that regulate the activity of proteins such as C20orf77. Leflunomide inhibits dihydroorotate dehydrogenase, which can reduce the synthesis of proteins that are part of C20orf77's pathway, resulting in functional inhibition. Lastly, Bortezomib, as a proteasome inhibitor, causes the accumulation of misfolded proteins, disrupting cellular homeostasis and potentially inhibiting the function of C20orf77 through stress-induced pathways. Each chemical operates by disrupting specific pathways or cellular processes that are crucial for the proper functioning of C20orf77, thereby achieving inhibition.
VOIR ÉGALEMENT...
Items 1 to 10 of 12 total
Afficher:
| Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Inhibe CDK4/6 impliqué dans la progression du cycle cellulaire, ce qui pourrait réduire l'activité de C21orf77 s'il est associé au cycle cellulaire. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Cible la tyrosine kinase de l'EGFR, inhibant potentiellement les voies de signalisation en aval impliquant C21orf77. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Inhibe BRAF V600E, affectant potentiellement les voies de signalisation qui incluent C21orf77 dans les cellules de mélanome. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Inhibe la phosphorylation et l'activation de l'AKT, inhibant potentiellement les voies de signalisation qui incluent C21orf77. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Inhibe la HMG-CoA réductase, affectant potentiellement les radeaux lipidiques et les voies de signalisation associées impliquant C21orf77. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibe mTOR, ce qui pourrait inhiber les voies de signalisation qui impliquent C21orf77, en affectant ses interactions protéiques ou sa localisation. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Modifie la dégradation de protéines spécifiques via le complexe E3 ubiquitine ligase; pourrait inclure C21orf77 s'il s'agit d'une cible de ce complexe. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Inhibe la kinase ROCK, affectant potentiellement l'organisation du cytosquelette et les voies de signalisation qui impliquent C21orf77. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibe MEK, ce qui pourrait modifier la signalisation de la voie ERK impliquant C21orf77. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibe JNK, ce qui pourrait affecter les voies de signalisation qui impliquent C21orf77, si la signalisation JNK module son activité. | ||||||